Spaulding Clinical Research, the US-based provider of clinical pharmacology and cardiac core-laboratory services is extending its reach further east through an alliance with Frontage Laboratories, according to PharmaTimes.
Under the strategic partnership agreement, Spaulding will conduct all intense electrocardiographic (ECG) studies on behalf of Frontage at its US clinical pharmacology unit in West Bend, Wisconsin as well as providing ECG Core Lab services for its partner.
Frontage, a full-service clinical research organization with facilities in the US and China, will in return offer bioanalytical method development and sample processing, formulation development and clinical trial product supplies on Spaulding’s behalf while serving as one of the clinical sites for Spaulding Clinical clients in China.
Randy Spaulding, chief executive officer and founder of Spaulding Clinical, said the collaboration was “another step forward in meeting our strategic objectives of providing the highest quality global clinical development facilities to our clients interested in accelerating drug development. Together, Frontage and Spaulding Clinical will deliver the first US-based fully-automated Clinical Pharmacology unit in China.”